Hepatocellular carcinoma
Drug research and approvals for hepatocellular carcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 656 studies of hepatocellular carcinoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 54 drug trials for it since 2013, FDA has 15 approved and 92 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 656
- Trials authorized in Canada: 54
- FDA orphan approvals: 15
- EU medicines: 3
Recruiting Now
Newest start dates first, of 656 recruiting on ClinicalTrials.gov ↗- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in…NCT07430202 · Phase 1 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · starts Oct 28, 2026
- Anatomic Versus Nonanatomic Liver Resection After Conversion Therapy for Hepatocellular CarcinomaNCT07927452 · Not reported · Sun Yat-sen University · starts Oct 25, 2026
- Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular CarcinomaNCT07836530 · Phase 3 · BeOne Medicines · starts Oct 23, 2026
- ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced HepatocellularNCT07813572 · Phase 3 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · starts Oct 20, 2026
- STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular CarcinomaNCT07863258 · Not reported · Universitaire Ziekenhuizen KU Leuven · starts Oct 15, 2026
- PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver CancerNCT07884877 · Phase 2 · Samsung Medical Center · starts Oct 15, 2026
- Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular CarcinomaNCT07840092 · Not reported · Tianjin Medical University Cancer Institute and Hospital · starts Oct 12, 2026
- Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast CancerNCT07880106 · Not reported · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · starts Oct 12, 2026
- GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular CancerNCT07627191 · Early Phase 1 · University of Arizona · starts Oct 7, 2026
- Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein…NCT07776080 · Phase 2 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · starts Oct 1, 2026
Trials Authorized in Canada
The 10 newest of 54; search them all in Canada trials| Apr 30, 2025 | A phase II study of stride (durvalumab + tremelimumab) with lenvatinib versus stride alone in patients with unresectable hepatocellular carcinoma (stride-hcc)LENVIMA / IMFINZI / IMJUDO | CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY | Ongoing |
| Apr 7, 2025 | Radiation therapy followed by durvalumab (medi4736) and tremelimumab and surgery versus radiation therapy followed by surgery for resectable hepatocellular…IMFINZI (DURVALUMAB) / TREMELIMUMAB | HAMILTON HEALTH SCIENCES CORPORATION | Ongoing |
| Mar 21, 2025 | A randomized phase 2 study of casdozokitug in combination with toripalimab plus bevacizumab in participants with unresectable and/or locally advanced or…CASDOZOKITUG (SRF388 (CHS-388)) / AVASTIN (BEVACIZUMAB) / TORIPALIMAB | Coherus BioSciences, Inc. | Ongoing |
| Feb 28, 2025 | A phase III, randomised, open-label, sponsor-blinded, multicentre study of rilvegostomig in combination with bevacizumab with or without tremelimumab as…IMJUDO / RILVEGOSTOMIG (AZD2936) / AVASTIN | AstraZeneca Pharmaceuticals LP | Ongoing |
| Dec 30, 2024 | A multicenter, open-label, first-in-human study of tyra-430 in advanced hepatocellular carcinoma and other solid tumors with activating fgf/fgfr pathway…TYRA-430 | TYRA BIOSCIENCES INC. | Ongoing |
| Dec 13, 2024 | A multicenter, open label, non-randomized first-in-human phase 1 dose escalation and expansion study to evaluate the safety, tolerability,pharmacokinetics, and…BAY 3547926 / BAY 3547922 / ATEZOLIZUMAB / BEVACIZUMAB | Bayer | Ongoing |
| Jul 5, 2023 | A phase 1 study of incb099280 in combination with ipilimumab in participants with select solid tumorsINCB099280 / IPILIMUMAB | Incyte Corporation | Closed |
| Apr 4, 2023 | A phase 1/2 exploratory study of the tbl1 inhibitor, tegavivint (bc2059), in patients with advanced hepatocellular carcinomaTEGAVIVINT (BC2059) / PEMBROLIZUMAB | ITERION THERAPEUTICS | Pending |
| Oct 18, 2022 | Perioperative therapy with durvalumab plus tremelimumab for patients with resectable hepatocellular carcinoma (hcc) - a phase II trial (neotoma)IMFINZI / TREMELIMUMAB | UNIVERSITY HEALTH NETWORK | Ongoing |
| Jun 1, 2022 | Atezolizumab and bevacizumab pre-liver transplantation for patients with hepatocellular carcinoma beyond milan criteria: a feasibility studyTECENTRIQ / AVASTIN | HOUSTON METHODIST RESEARCH INSTITUTE | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 107| Apr 11, 2025 | Opdivoin combination with ipilimumab, for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma… | Bristol-Myers Squibb Company | Approved |
| Jan 25, 2024 | Keytrudatreatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a… | MSD International Business GmbH | Approved |
| Oct 21, 2022 | ImfinziIn combination with tremelimumab-actl for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) | AstraZeneca Pharmaceuticals LP | Approved |
| Oct 21, 2022 | ImjudoIn combination with durvalumab for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) | AstraZeneca Pharmaceuticals LP | Approved |
| May 29, 2020 | Tecentriq and AvastinAVASTIN, in combination with atezolizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have… | Genentech, Inc. | Approved |
| May 29, 2020 | Tecentriq and AvastinTECENTRIQ, in combination with bevacizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have… | Genentech, Inc. | Approved |
| Mar 10, 2020 | OPDIVOOPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC)… | Bristol-Myers Squibb Company | Approved |
| May 10, 2019 | CYRAMZACYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein… | Eli Lilly and Company | Approved |
| Jan 14, 2019 | CABOMETYXCABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. | Exelixis, Inc. | Approved |
| Nov 9, 2018 | KeytrudaKEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib | MSD International Business GmbH | Approved |
| Aug 15, 2018 | LENVIMALENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) | Eisai Inc. | Approved |
| Sep 22, 2017 | OPDIVOTreatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (Indication withdrawn) | Bristol-Myers Squibb Company | Approved |
| Apr 27, 2017 | StivargaTreatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib. | Bayer HealthCare Pharmaceuticals, Inc. | Approved |
| Apr 4, 2014 | LipiodolSelective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC) | Guerbet LLC | Approved |
| Nov 16, 2007 | NexavarTreatment of unresectable hepatocellular carcinoma | Bayer Pharmaceuticals Corporation | Approved |
Medicines Authorised in the EU
Newest first| Feb 20, 2023 | Imjudotremelimumab | AstraZeneca AB | EMA ↗ |
| Nov 9, 2022 | Sorafenib Accordsorafenib · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Jul 19, 2006 | Nexavarsorafenib | Bayer AG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA